A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

NCT01234597 Phase 4 COMPLETED

Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal insulin or mixed insulin, requiring treatment with basal plus regimen

Details

Lead sponsor	Sanofi
Phase	Phase 4
Status	COMPLETED
Enrolment	219
Start date	2012-12
Completion	2015-04

Conditions

• Diabetes Mellitus, Type 2

Interventions

• INSULIN GLARGINE (HOE901)
• INSULIN GLULISINE (HMR1964)

Primary outcomes

• Changes in Hemoglobin A1c (HbA1c) level — Baseline, week 24

Countries

Israel